MARKET COMPOSITE
TXG - 10x Genomics Inc8:00:00 PM 3/28/2024
Price
$37.53
+ 0.64 (1.73%)
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. 10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment for use in cellular biology. Prior to starting the company, Saxonov was the founding architect, and director of research and development at 23andMe. Ness left 10x Genomics in December 2016 and in 2018, Justin McAnear, Tesla's former finance chief joined the company as CFO.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue184MM+20%
Gross Profit115.8MM+21%
Cost Of Revenue68.2MM+17%
Operating Income-55.2MM-42%
Operating Expenses171MM-10%
Net Income-49MM-47%
R&D65.3MM-2%
G&A86.1MM+5%
Interest Expense8K-
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized re

    In this article, we will be taking a look at 11 oversold healthcare stocks to buy right now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Oversold Healthcare Stocks To Buy Right Now. The Healthcare Sector: The New 2024 Idea? The healthcare sector has been popular […]

    The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime. Curing these diseases would be invaluable. The likelihood of that happening is something one can only dream of today. Yet based on research from Wood’s Ark Invest, the companies pursuing these treatments could see their enterprise value race higher by a 28% compounded annual growth rate. That me

    The popular money manager added to these three existing positions on Monday following disappointing financial updates earlier this month.

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m. Eastern Time.

    10x Genomics, Inc. (NASDAQ:TXG) Q4 2023 Earnings Call Transcript February 15, 2024 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.36. 10x Genomics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]

    Q4 2023 10X Genomics Inc Earnings Call

    Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.